News Releases

resTORbio Reports Second Quarter 2018 Financial Results

Phase 2b results identify dose and patient population for pivotal program with RTB101 Initiation of pivotal program with RTB101 expected in the first half of 2019 BOSTON , Aug. 09, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping

Aug 09, 2018
resTORbio Announces Science Translational Medicine Publication of Phase 2a Data Showing Improvement in Immune Function and Decreased Infection Rates in People Aged 65 Years and Older

resTORbio’s TORC1 inhibitors enhanced the function of the aging immune system and were associated with a statistically significant decrease in the incidence of all infections, including respiratory tract infections, in older people   Respiratory tract infections are the 4 th leading cause of

Jul 11, 2018
resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition

BOSTON , May 22, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced it

May 22, 2018
resTORbio Reports First Quarter 2018 Financial Results

Last patient dosed in Phase 2b trial; topline data now expected in third quarter of 2018 BOSTON , May 10, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization

May 10, 2018
resTORbio Announces Formation of Clinical Advisory Board
Esteemed Experts Engaged as Company Advances Clinical Development Program Phase 2b Data for Lead Program Expected in the Second Half of 2018 BOSTON , March 19, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC) today announced the formation of a clinical advisory board (CAB) to support the
Mar 19, 2018